The challenges of clinical trials in fragile X syndrome.
about
Advances in the Understanding of the Gabaergic Neurobiology of FMR1 Expanded Alleles Leading to Targeted Treatments for Fragile X Spectrum DisorderDysregulation and restoration of translational homeostasis in fragile X syndromeFragile X syndrome as a rare disease in China - Therapeutic challenges and opportunitiesLearning and behavioral deficits associated with the absence of the fragile X mental retardation protein: what a fly and mouse model can teach us.From Learning to Memory: What Flies Can Tell Us about Intellectual Disability TreatmentTargeted pharmacological treatment of autism spectrum disorders: fragile X and Rett syndromesStructural-functional connectivity deficits of neocortical circuits in the Fmr1 (-/y) mouse model of autism.Therapeutic Strategies in Fragile X Syndrome: From Bench to Bedside and BackPrader-Willi syndrome mental health research strategy workshop proceedings: the state of the science and future directionsFMRP Expression Levels in Mouse Central Nervous System Neurons Determine Behavioral Phenotype.Dysregulated nitric oxide signaling as a candidate mechanism of fragile X syndrome and other neuropsychiatric disorders.A combination of ascorbic acid and α-tocopherol to test the effectiveness and safety in the fragile X syndrome: study protocol for a phase II, randomized, placebo-controlled trialProtein expression of targets of the FMRP regulon is altered in brains of subjects with schizophrenia and mood disorders.Autism spectrum disorder: an omics perspective.Annual research review: Rare genotypes and childhood psychopathology--uncovering diverse developmental mechanisms of ADHD risk.The utility of rodent models of autism spectrum disordersOxytocin: parallel processing in the social brain?Metabotropic glutamate receptor subtype 5: molecular pharmacology, allosteric modulation and stimulus biasThe complex genetics in autism spectrum disorders.Molecular medicine of fragile X syndrome: based on known molecular mechanisms.Public Health Literature Review of Fragile X Syndrome.Pharmacological Treatments for Autism Spectrum Disorder: Will Emerging Approaches Yield New Treatments?Clinical trials for neurodevelopmental disorders: At a therapeutic frontier.Emerging Genetic Counselor Roles within the Biotechnology and Pharmaceutical Industries: as Industry Interest Grows in Rare Genetic Disorders, How are Genetic Counselors Joining the Discussion?Intragenic FMR1 disease-causing variants: a significant mutational mechanism leading to Fragile-X syndrome.Social/economic costs and health-related quality of life in patients with fragile X syndrome in Europe.A brain proteomic investigation of rapamycin effects in the Tsc1+/- mouse model.Are there new advances in the pharmacotherapy of autism spectrum disorders?Altered surface mGluR5 dynamics provoke synaptic NMDAR dysfunction and cognitive defects in Fmr1 knockout mice.Pharmacological Rescue of Hippocampal Fear Learning Deficits in Fragile X Syndrome.A Retrospective Video Analysis of Canonical Babbling and Volubility in Infants with Fragile X Syndrome at 9-12 Months of Age.Autism spectrum disorders--an emerging area in psychopharmacology.Validity of a condition specific outcome measure for fragile X syndrome: the Aberrant Behaviour Checklist-utility index.Protein synthesis levels are increased in a subset of individuals with Fragile X syndrome.
P2860
Q26781265-F4F3EF10-A08C-4E8F-B0BA-A3965BFB9903Q26782616-79874D8F-E0AF-4F0F-8225-83517AC6A154Q26863615-01053EFF-AA7A-41A5-9B13-04533741AA4DQ26866506-11F82DE9-BB1E-4030-BA35-319B0D3BD883Q27020947-9DAADC92-7CB5-4BEE-B181-2615DF8FAE6EQ27023257-97208EE0-542E-4784-87A4-B82BF635AB47Q27336359-2FC3BD16-ADBA-44E4-9C5E-3E26A34BB94FQ27337360-A6455C79-81F9-41BF-AD5C-628C08A81319Q28074923-5B5377B7-0D90-434C-B271-CD114D72669AQ30365865-4D731E83-4AED-46CA-9825-7BC4A62BAFCAQ33929361-305FCEBC-9129-4C9E-A47B-2EC354AA3B58Q34207747-C3EA8FBE-1450-4D23-BE39-B164E731FA89Q37286894-E5EE02F4-4E55-47E4-8DDB-A699080954C9Q38259780-1CFCB421-3E11-408F-AD54-02D171A3455CQ38286122-58597FD9-59CE-44B2-BC44-4D5833FF3C2FQ38367189-AA0BAF01-93BC-4F76-9DC3-1AEEE30DA42BQ38442124-3B1055F1-C189-491C-B3D6-9467435FE787Q38567309-D5B1B820-7ED9-42FE-8A4F-D7EDF7EE952FQ38579867-ED2152D1-08C9-4457-A7D2-995D0C294AA4Q38627691-71AAD781-3716-4733-9476-EFDBCF3E94EBQ38641503-087C8DB7-2D43-4DCD-B56A-8019DF6735D0Q38666640-CC25451B-F3F0-4A8D-A9E3-3D11781A23ADQ38695866-EB9ECEA7-BEE7-46FC-B1EC-8505EF630F2AQ38889756-072C4215-93FB-4BCA-84FB-62D2AFC26808Q39125843-5587C61F-26FE-46D7-88AA-BAEE962807BDQ39855919-63476A67-68FD-430D-8238-170AE48F30ADQ41211684-39B61023-6761-4623-9A1E-7EA0CFCEEF2AQ42327831-980DF1D4-83E8-4520-87F3-8772BAB70DC5Q42645980-528A5FD0-CD5D-4E29-9CEB-255196B4B452Q47412555-8AE6772E-4A1A-4591-A3C0-F3C281049D49Q50309336-588DE3BD-8CF7-43A6-84DC-81AF1347F5EAQ50343855-F106D350-3E4E-4D23-AE9D-F89EE4776EA1Q50540126-3B8B9BD5-A8D1-4B9F-B920-2082B58DA5AEQ51733403-F1158174-F8EA-4A7A-95B9-C98378FB74F3
P2860
The challenges of clinical trials in fragile X syndrome.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 31 October 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
The challenges of clinical trials in fragile X syndrome.
@en
The challenges of clinical trials in fragile X syndrome.
@nl
type
label
The challenges of clinical trials in fragile X syndrome.
@en
The challenges of clinical trials in fragile X syndrome.
@nl
prefLabel
The challenges of clinical trials in fragile X syndrome.
@en
The challenges of clinical trials in fragile X syndrome.
@nl
P2093
P2860
P1433
P1476
The challenges of clinical trials in fragile X syndrome.
@en
P2093
Baltazar Gomez-Mancilla
Elizabeth Berry-Kravis
Fabrizio Gasparini
Florian von Raison
George Apostol
Randi Hagerman
Sébastien Jacquemont
Vincent Des Portes
P2860
P2888
P304
P356
10.1007/S00213-013-3289-0
P577
2013-10-31T00:00:00Z
2014-03-01T00:00:00Z